Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Medtronic
US Department of Justice
Mallinckrodt
Cantor Fitzgerald
McKinsey
Harvard Business School
Julphar

Generated: January 19, 2019

DrugPatentWatch Database Preview

Theratechnologies Company Profile

« Back to Dashboard

What is the competitive landscape for THERATECHNOLOGIES, and when can generic versions of THERATECHNOLOGIES drugs launch?

THERATECHNOLOGIES has one approved drug.

There are five US patents protecting THERATECHNOLOGIES drugs.

There are forty-two patent family members on THERATECHNOLOGIES drugs in sixteen countries.

Summary for Theratechnologies
International Patents:42
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Theratechnologies

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes 8,435,945 ➤ Try a Free Trial ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes 7,316,997 ➤ Try a Free Trial ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes 7,316,997 ➤ Try a Free Trial ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes 8,314,066 ➤ Try a Free Trial ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes 5,861,379 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes 7,144,577 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Theratechnologies

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 6,020,311 ➤ Try a Free Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 6,020,311 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Theratechnologies Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2004105789 ➤ Try a Free Trial
Spain 2163020 ➤ Try a Free Trial
Australia 2005297366 ➤ Try a Free Trial
Japan H11505807 ➤ Try a Free Trial
Germany 1109909 ➤ Try a Free Trial
Australia 5683396 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Fish and Richardson
Accenture
US Department of Justice
Colorcon
Cipla
Boehringer Ingelheim
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.